The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.
Bangkok, Thailand. In J Neuropathol Exp Neurol, Jan 2016
This review summarizes the current experience using immunohistochemistry of glioma samples to identify mutations in IDH1, TP53, ATRX, histone H3 genes, BRAF, EGFR, MGMT, CIC, and FUBP1 as well as guidelines for prudent use of DNA sequencing as a supplemental method.
Biomarker-driven diagnosis of diffuse gliomas.
Atlanta, United States. In Mol Aspects Med, Nov 2015
Oligodendrogliomas are also IDH mutant, but instead are characterized by 1p/19q co-deletion and mutations of CIC, FUBP1, Notch1 and the TERT promoter.
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
Boston, United States. In Cns Oncol, Oct 2015
More recently, recurrent molecular genetic alterations have been identified to occur concurrently with 1p/19q-codeletion, and definitively identify these tumors, including mutations in IDH1/2, CIC, FUBP1, and the TERT promoter, as well as the absence of ATRX and TP53 alterations.
Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.
Houston, United States. In Semin Radiat Oncol, Jul 2015
In this review, we discuss the effect of the most critical molecular alterations described in diffuse (IDH1/2, 1p/19q codeletion, ATRX, TERT, CIC, and FUBP1) and circumscribed (BRAF-KIAA1549, BRAF(V600E), and C11orf95-RELA fusion) gliomas.
Mutations in CIC and FUBP1 contribute to human oligodendroglioma.
Baltimore, United States. In Science, 2011
CIC gene was mutated in 6 oligodendrogliomas and FUBP1 gene was mutated in 2; 27 additional oligodendrogliomas showed 12 and 3 more tumors with mutations of CIC and FUBP1; results suggest role of these genes in biology and pathology of oligodendrocytes